DYN
Price
$11.90
Change
+$0.14 (+1.19%)
Updated
May 22, 04:59 PM (EDT)
Capitalization
1.34B
70 days until earnings call
ERAS
Price
$1.21
Change
-$0.01 (-0.82%)
Updated
May 22, 04:59 PM (EDT)
Capitalization
345.61M
77 days until earnings call
Interact to see
Advertisement

DYN vs ERAS

Header iconDYN vs ERAS Comparison
Open Charts DYN vs ERASBanner chart's image
Dyne Therapeutics
Price$11.90
Change+$0.14 (+1.19%)
Volume$25.45K
Capitalization1.34B
Erasca
Price$1.21
Change-$0.01 (-0.82%)
Volume$11.77K
Capitalization345.61M
DYN vs ERAS Comparison Chart
Loading...
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DYN vs. ERAS commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYN is a Buy and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (DYN: $11.76 vs. ERAS: $1.22)
Brand notoriety: DYN and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYN: 58% vs. ERAS: 32%
Market capitalization -- DYN: $1.34B vs. ERAS: $345.61M
DYN [@Biotechnology] is valued at $1.34B. ERAS’s [@Biotechnology] market capitalization is $345.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.18B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYN’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • DYN’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, both DYN and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYN’s TA Score shows that 6 TA indicator(s) are bullish while ERAS’s TA Score has 3 bullish TA indicator(s).

  • DYN’s TA Score: 6 bullish, 4 bearish.
  • ERAS’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, DYN is a better buy in the short-term than ERAS.

Price Growth

DYN (@Biotechnology) experienced а +0.51% price change this week, while ERAS (@Biotechnology) price change was -3.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.82%. For the same industry, the average monthly price growth was +7.45%, and the average quarterly price growth was -1.67%.

Reported Earning Dates

DYN is expected to report earnings on Jul 31, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.82% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DYN($1.34B) has a higher market cap than ERAS($346M). DYN (-50.085) and ERAS (-51.394) have similar YTD gains . ERAS has higher annual earnings (EBITDA): -151.33M vs. DYN (-395.31M). DYN has more cash in the bank: 677M vs. ERAS (319M). DYN has less debt than ERAS: DYN (23.3M) vs ERAS (52.9M). DYN (0) and ERAS (0) have equivalent revenues.
DYNERASDYN / ERAS
Capitalization1.34B346M386%
EBITDA-395.31M-151.33M261%
Gain YTD-50.085-51.39497%
P/E RatioN/AN/A-
Revenue00-
Total Cash677M319M212%
Total Debt23.3M52.9M44%
TECHNICAL ANALYSIS
Technical Analysis
DYNERAS
RSI
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 21 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 16 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JFESX37.99N/A
N/A
JPMorgan Europe Dynamic I
FIAGX21.89N/A
N/A
Fidelity Advisor International Growth A
BUFGX34.39N/A
N/A
Buffalo Growth
KNPCX134.81N/A
N/A
Kinetics Paradigm Adv C
BRZAX12.79-0.09
-0.70%
BlackRock Sus Adg Intl Eq Inv A

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with CRNX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
-4.70%
CRNX - DYN
52%
Loosely correlated
-4.53%
RNA - DYN
52%
Loosely correlated
-3.22%
ERAS - DYN
51%
Loosely correlated
-4.69%
RVMD - DYN
50%
Loosely correlated
-4.27%
XNCR - DYN
49%
Loosely correlated
-7.62%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-4.69%
XNCR - ERAS
57%
Loosely correlated
-7.62%
RVMD - ERAS
54%
Loosely correlated
-4.27%
KYMR - ERAS
54%
Loosely correlated
-4.17%
BEAM - ERAS
54%
Loosely correlated
-2.99%
RCKT - ERAS
53%
Loosely correlated
-3.80%
More